Pacer Advisors, Inc. Genmab A/S Transaction History

Pacer Advisors, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 12, 2023	BUY	$37.4 - $42.94 $27,676 - $31,775	740 Added 14.6%	5,810 $220,000
Q1 2023 May 02, 2023	BUY	$34.88 - $43.22 $5,650 - $7,001	162 Added 3.3%	5,070 $191,000
Q4 2022 Feb 06, 2023	BUY	$33.8 - $47.06 $165,890 - $230,970	4,908 New	4,908 $208,000
Q1 2022 Apr 05, 2022	SELL	$30.95 - $39.68 $157,349 - $201,733	-5,084 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$35.87 - $47.12 $6,528 - $8,575	-182 Reduced 3.46%	5,084 $201,000
Q3 2021 Oct 15, 2021	BUY	$41.55 - $48.72 $6,731 - $7,892	162 Added 3.17%	5,266 $230,000
Q1 2021 Apr 05, 2021	SELL	$30.92 - $44.4 $8,348 - $11,988	-270 Reduced 5.02%	5,104 $168,000
Q4 2020 Jan 20, 2021	SELL	$33.66 - $40.76 $39,988 - $48,422	-1,188 Reduced 18.1%	5,374 $219,000
Q3 2020 Oct 19, 2020	BUY	$33.07 - $38.68 $217,005 - $253,818	6,562 New	6,562 $240,000

240

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.